Broker’s call: Dr Lal Pathlabs

Target: ₹2,100CMP: ₹1,951.85Dr Lal Pathlabs (DLPL) has announced the acquisition of SN Genelab — a B2B diagnostics operator focused on advanced genomics and molecular pathology testing — for ₹168 crore (70 per cent stake), thus valuing the company at around 16x FY26 EV/EBITDA.We expect the company…